article Open AccessTop 1% cited

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Annals of Oncology · 2019 · Vol. 30(4) · pp. 582–588

Omid Hamid✉(Angeles Clinic and Research Institute)Caroline Robert(Institut Gustave Roussy)Adil Daud(University of California, San Francisco)F. Stephen Hodi(Dana-Farber Cancer Institute)Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center)Richard Kefford(The University of Sydney)Jedd D. Wolchok(Memorial Sloan Kettering Cancer Center)Peter Hersey(The University of Sydney)Richard W. Joseph(Mayo Clinic in Florida)Jeffrey S. Weber(NYU Langone Health)Roxana Dronca(Mayo Clinic in Florida)Tara C. Mitchell(University of Pennsylvania)Amita Patnaik(South Texas Accelerated Research Therapeutics)Hassane M. Zarour(UPMC Hillman Cancer Center)Anthony M. Joshua(UNSW Sydney)Qi Zhao(Merck & Co., Inc., Rahway, NJ, USA (United States))E. Jensen(Merck & Co., Inc., Rahway, NJ, USA (United States))S. Ahsan(Merck & Co., Inc., Rahway, NJ, USA (United States))Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States))Antoni Ribas(University of California, Los Angeles)

View via DOI Full-text PDF

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Immunotherapy and Immune ResponsesMedicinePembrolizumabExpanded accessOncologyMelanomaInternal medicineCancerImmunotherapyCancer research

MeSH terms

Antineoplastic Agents, ImmunologicalAdultDrug Administration ScheduleFollow-Up StudiesHumansMelanomaSkin NeoplasmsKaplan-Meier EstimateAntibodies, Monoclonal, HumanizedResponse Evaluation Criteria in Solid Tumors